

CURRICULUM VITAE



PERSONAL DATA:

Name: Christine Bezombes
Date of Birth: December 20, 1971
Place of Birth: Marrakech, Morocco
Citizenship: France
Marital status: divorced, 2 children
Address: CRCT, U1037, 2 Avenue Hubert Curien, 31100 Toulouse, France
email: christine.bezombes@inserm.fr
Webmail: <https://www.crct-inserm.fr/09-j-j-fournie/>
Web of Sciences: AAC-1724-2020

RESEARCH INTERESTS:

NHL/monoclonal antibodies/3D model/ preclinical drug screening/immune contexture

EDUCATION AND TRAINING:

- Since 2021** Researcher in Pr C Laurent's laboratory, CRCT U1037, Toulouse, France
- 2007-2020** Researcher in Dr JJ Fournié's laboratory, CRCT U1037, Toulouse, France
- 2005-2006** Researcher in Pr G Laurent's laboratory, INSERM U563, Toulouse, France
- 2001-2004** Postdoctoral fellow in Pr G Laurent's laboratory. "Effect of Rituximab on follicular lymphoma cells: involvement of raft microdomains and the acidic sphingomyelinase". INSERM U563, Toulouse, France.
- 2000-2001** Postdoctoral fellow in Dr J Moscat's laboratory, "Role of p62 in TNFa signaling and role of PKCzeta in apoptosis induced by antitumoral agents in myeloid leukemic cells". Center of Molecular Biology "Severo Ochoa", Universidad Autonoma, Madrid, Spain.
- 1997** Internship in Pr B Aggarwal's laboratory. MD Anderson Cancer Center (Houston, USA).
- 1996- 1999** PhD student in Biochemistry & Cell Biology, "Involvement of the sphingomyelin-ceramide pathway in the effect of antitumoral agents in acute myeloid leukemia cells", Université Paul Sabatier, Pr G Laurent's laboratory, Toulouse, France.
- 1995** M. S., in Physiopathology, Université Paul Sabatier, Toulouse, France.
- 1994** B. S. in Cell Biology, Université Paul Sabatier, Toulouse, France.

Publications

Bezombes C, Pérez-Galán P. Immunotherapies in Non-Hodgkin's Lymphoma. *Cancers (Basel)*. 2021 Jul 20;13(14):3625.

Gava F^s, Faria C^s, Gravelle P, Valero J, Dobaño-López C, Morin R, Norlund M, Gomes A, Lagarde JM, Rossi C, Bordenave J, Pieruccioni L, Rouquette J, Matas-Céspedes A, Fournié JJ, Ysebaert L, Laurent C, Pérez-

Galán P and **Bezombes C**. 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma. *Cancers (Basel)* March 2021. (§ co-authors)

Rossi R, Tosolini M, Gravelle P, Pericart S, Kanoun S, Evrard S, Gilhodes J, Franchini DM, Amara N, Charlotte Syrykh C, Bories P, Oberic O, Ysebaert L, Marti M, Ramla S, Robert P, Taboure t-Viaud C, Casasnovas RO, Fournié JJ, **Bezombes C**[§] and Laurent C[§]. (§ co-authors) Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma *Haematologica*, 2020.

Bordes J, Sébastien Incerti S, Mora-Ramirez E, Tranel J, Rossi C, **Bezombes C**, Bordenave J, Bardiès M, Brown R, Bordage MC. Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy. *Medical Physics*, 2020.

Vidal-Crespo A, Sanjuan-Pla A, Roué G, Menéndez P, Matas-Céspedes A, Rodriguez V, López-Guillermo A, Giné E, Campo E, Colomer D, **Bezombes C**, Lammerts van Bueren J, Chiu C, Doshi P, Rossi C, Perez-Galan P. Daratumumab shows anti-tumor activity in vitro and in vivo models of B cell non-Hodgkin lymphoma and improves response to standard chemo-immunotherapy regimens. *Haematologica*. 2020 Apr;105(4):1032-1041.

Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina S, Fournié JJ, **Bezombes C**. A tridimensional model for NK cell-mediated ADCC of Follicular Lymphoma. *Frontiers in Immunology*. 2019 Aug 14;10:1943.

Phonesouk E, Lechevallier S, Ferrand A, Rols MP, **Bezombes C**, Verelst M, Golzio M. Increased uptake of silica nanoparticles by electroporation: from cellular characterization to potential applications. *Materials (Basel)*. 2019 Jan 7;12(1).

Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini DM, Laurent C, Ysebaert L, Ligat L, Jean C, Savina A, Klein C, Matas Céspedes A, Perez-Galan P, Fournié JJ, **Bezombes C**. Boosting $\gamma\delta$ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. *Oncoimmunol*. 2018 Dec 17;8(3):1554175.

Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, **Bezombes C**, Laurent G, Brousset P, Fournié JJ, Laurent C. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. *Cancers*. 2018 Oct 31;10(11).

Gravelle P, Burroni B, Péricart S, Rossi C, **Bezombes C**, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. *Oncotarget*. 2017 Mar 29.

Duault C, Betous D, **Bezombes C**, Roga S, Cayrol C, Girard JP, Fournié JJ, Poupot M. IL-33-expanded human V γ 9V δ 2 T cells have anti-lymphoma effect in a mouse tumor model. *Eur J Immunol*. 2017 Jul 25. doi: 10.1002/eji.201747093.

Fontan C, **Bezombes C**, Salabert AS, Costes J, Lopez R, Fournie JJ, Avet-Loiseau H, Coulais Y, Payoux P, Tafani M. Radiolabelling rituximab with 99m Tc in three steps procedure. *J Labelled Comp Radiopharm*. 2015 May 27.

Decaup E, Duault C, **Bezombes C**, Poupot M, Olive D, Fournié JJ. Similar signaling to phosphoantigens and butyrophilin A3 in human TCRV γ 9+ $\gamma\delta$ T lymphocytes. *Immunol Lett*. 2014 Jun 9.

- Gravelle P, Jean C, Familiades J, Decaup E, Blanc A, **Bezombes-Cagnac C**, Laurent C, Savina A, Fournié JJ, Laurent G. Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma. *Am J Pathol*. 2014 Jan;184(1):282-95.
- Kheirallah S, Fruchon S, Ysebaert L, Blanc A, Capilla F, Marrot A, Alsaati T, Frenois FX, Benhadji KA, Fournié J, Laurent G, **Bezombes C**. p90RSK: a new target of Enzastaurin in follicular lymphoma cells. *Br J Pharmacol*. 2013 Aug 28.
- Decaup E, Jean C, Laurent C, Gravelle P, Fruchon S, Capilla F, Marrot A, Al Saati T, Frenois FX, Laurent G, Klein C, Varoqueaux N, Savina A, Fournié JJ, **Bezombes C**. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. *Blood Cancer J*. 2013 Aug 9;3:e131.
- Fournié JJ, Sicard H, Poupot M, **Bezombes C**, Blanc A, Romagné F, Ysebaert L, Laurent G. [What lessons can be learned from \$\gamma\delta\$ T cell-based cancer immunotherapy trials?](#) *Cell Mol Immunol*. 2013 Jan;10(1):35-41.
- Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L, Fournié JJ, Laurent G, **Bezombes C**. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. *Leukemia*. 2012 Apr;26(4):795-805.
- Bezombes C**, Fournié JJ, Laurent G. Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives. *Mol Cancer Res*. 2011 Sep 15.
- Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, **Bezombes C**, Quillet-Mary A, Poupot M, Ysebaert L, Laurent G, Fournié JJ. Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies. *Curr Drug Targets*. 2010 Jul;11(7):790-800.
- Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournié JJ, Laurent G, **Bezombes C**. Rituximab inhibits B cell receptor signalling. *Blood*. 2010 Feb 4;115(5):985-94
- Gertner-Dardenne J, Bonnafous C, **Bezombes C**, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Yesebaert L, Laurent G, Sicard H, Fournié JJ. Bromohydrin pyrophosphate enhances ADCC induced by therapeutic antibodies. *Blood*. 2009 May 14;113(20):4875-84
- Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D, **Bezombes C**. PKCz-mTOR pathway: a new target for rituximab therapy in follicular lymphoma. *Blood*. 2008 Jan 1;111(1):285-91.
- Charruyer A, Jean C, Colomba A, Jaffrezou JP, Quillet-Mary A, Laurent G, **Bezombes C**. PKCzeta protects against UV-C induced apoptosis by inhibiting acid sphingomyelinase-dependent ceramide production. *Biochem J*. 2007 Jul 1;405(1):77-83.
- Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, **Bezombes C**. Syk-dependent mTOR activation in follicular lymphoma cells. *Blood*. 2006 Dec 15;108(13):4156-62.
- Charruyer A, Grazide S, **Bezombes C**, Muller S, Laurent G, Jaffrezou JP. UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. *J Biol Chem*. 2005 May 13;280(19):19196-204.
- Bezombes C**, Grazide S, Fabre C, Quillet-Mary A, Müller S, Jaffrezou JP, Laurent G. Rituximab antiproliferative effect in B lymphoma cells is mediated by acid-sphingomyelinase activation into raft microdomains. *Blood*, 2004; 104:1166-73.

Plo I, Bono F, **Bezombes C**, Alam A, Bruno A, Laurent G. Nerve growth factor-induced protein kinase C stimulation contributes to TrkA-dependent inhibition of p75 neurotrophin receptor sphingolipid signaling. *J Neurosci Res*, 2004; 77:465-74.

Bezombes C, Laurent G, Jaffrézou JP. Implication of raft microdomains in drug induced apoptosis. *Curr. Med. Chem. Anti-Cancer Agents*, 2003, 3:263-70.

Mansat-De Mas V, Hernandez H, Plo I, **Bezombes C**, Maestre N, Quillet-Mary A, Flomenko R, Demur C, Jaffrézou J-P, Laurent G. Protein kinase C α -mediated Raf-1/extracellular-regulated activation by daunorubicin. *Blood*, 2003, 101: 543-50.

Maestre N, **Bezombes C**, Plo I, Levade T, Lavelle F, Laurent G, Jaffrézou JP. Phosphatidylcholine-derived phosphatidic acid and diacylglycerol are involved in the signaling pathways activated by docetaxel. *J. Exp. Ther. Oncol.*, 2003, 3:36-46.

Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrezou JP, Laurent G, Quillet-Mary A. Overexpression of protein kinase C ζ confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. *Mol Pharmacol*. 2002, 62:1446-55.

Terrisse AD, **Bezombes C**, Lerouge S, Laurent G, Jaffrezou JP. Daunorubicin- and Ara-C-induced interphasic apoptosis of human Type II leukemia cells is caspase-8-independent. *Biochim Biophys Acta*. 2002, 1584:99-103.

Grazide S, Maestre N, Veldman RJ, **Bezombes C**, Maddens S, Levade T, Laurent G, Jaffrezou JP. Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts. *FASEB J*. 2002, 16:1685-7.

Bezombes C, Plo I, Mansat-De Mas V, Quillet-Mary A, Negre-Salvayre A, Laurent G, Jaffrezou JP. Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C. *FASEB J*. 2001, 15:1583-5.

Bezombes C, Segui B, Cuvillier O, Bruno AP, Uro-Coste E, Gouaze V, Andrieu-Abadie N, Carpentier S, Laurent G, Salvayre R, Jaffrezou JP, Levade T. Lysosomal sphingomyelinase is not solicited for apoptosis signaling. *FASEB J*. 2001, 15:297-9.

Bezombes C, Segui B, Uro-Coste E, Medin JA, Andrieu-Abadie N, Auge N, Brouchet A, Laurent G, Salvayre R, Jaffrezou JP, Levade T. Stress-induced apoptosis is not mediated by endolysosomal ceramide. *FASEB J*. 2000, 14:36-47.

Mansat-de Mas V, **Bezombes C**, Quillet-Mary A, Bettaieb A, D'orgeix AD, Laurent G, Jaffrezou JP. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. *Mol Pharmacol*. 1999, 56:867-74.

Jaffrezou JP, Maestre N, de Mas-Mansat V, **Bezombes C**, Levade T, Laurent G. Positive feedback control of neutral sphingomyelinase activity by ceramide. *FASEB J*. 1998, 12:999-1006.

Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP. Restoration of TNF- α -induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. *FASEB J*. 1998, 12:101-9.

Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, **Bezombes C**, Maestre N, Vermeersch S, Rousse A, Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. *EMBO J*. 1996, 15:2417-24.

Bezombes C. What lessons we learned on tumor microenvironment using non-Hodgkin's lymphoma 3D cultures? The tumor and its microenvironment symposium. December 1st 2021. Oral presentation (invited)

Faria C, Gava F, Gravelle P, Valero JG, Dobaño-López C, Morin R, Norlund M, Gomes A, Lagarde JM, Fournié JJ, Ysebaert L, Laurent C, Pérez-Galán P and **Bezombes C.** Patient Derived Lymphoma Spheroids in personalized medicine: a new model to test immunotherapies. EACR Good Bye Flat Biology. October 5 & O 2021. eposter presentation.

Faria C, Gava F, Gravelle P, G. Valero J, Dobaño-López C, Morin R, Norlund M, Gomes A, Lagarde JM, Rossi C, Bordenave J, Pieruccioni L, Rouquette J, Matas-Céspedes A, Fournié JJ, Ysebaert L, Laurent C, Pérez-Galán P and **Bezombes C.** 3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma. EACR Imaging cancer virtual conferences September 29-30 2021. ePoster presentation.

Faria C, and **Bezombes C.** Patient Derived Lymphoma spheroids, a new pre-clinical model for Non-Hodgkin Lymphoma research. GSO Workshop. September 25th 2019. Oral presentation.

Faria C, Gava F, Gravelle P, Bordenave J, Chloé Laplagne, Mary Poupot, Pérez-Galán P, G. Valero J, Dobaño-López C, Lagarde JM, Morin R, Norlund M, Gomes A, Fournié JJ, Laurent C, and **Bezombes C.** Patient derived lymphoma spheroids. CRCT scientific retreat September 20th 2019. Poster presentation.

Rossi C, Kanoun S, Tosolini M, Pericart S, Gilhodes J, Franchini DM, Gravelle P, Amara N, Grevaz C, Bories P, Oberic L, Ysebaert L, Evrard S, Filleron T, Savina A, Casasnovas RO, Fournié JJ, Bezombes C*, Laurent C* (* co-last authors). Le SUVmax pré-thérapeutique est associé à la prolifération des cellules tumorales et non au micro-environnement immunitaire et prédit la survie sans progression des patients avec un lymphome folliculaire. SFH March 27-29 2019. Paris. Oral and poster presentation.

Rossi C, Kanoun S, Tosolini M, Péricard S, Gilhodes J, Franchini DM, Gravelle P, Amara N, Grevaz C, Bories P, Oberic L, Ysebaert L, Evrard S, Filleron T, Savina A, Casasnovas RO, Fournié JJ, **Bezombes C***, Laurent C* (* co-last authors). Genomic, immunophenotypic profiles and prognostic value of tumor SUVmax in follicular lymphoma patients: integration model of PET-FDG imaging data and FL biological analyses. 7th international workshop on PET in Lymphoma and Myeloma (PILM7). October 4-6 2018. Menton. Poster presentation.

Bordes J, Incerti S, Rossi C, Bordenave J, **Bezombes C**, Bardiès M and Bordage MC. Monte-Carlo modelling of energy deposition within a realistic 3D model of follicular lymphoma. Congress of the European Association of Nuclear Medicine. October 21-25 2017. Vienna. Austria. Oral presentation.

P. Pérez-Galán, A. Vidal-Crespo, A. Matas-Céspedes, V. Rodriguez, C. Rossi, G. Roué, A. López-Guillermo, E. Giné, E. Campo, D. Colomer, A. Wiestner, C. **Bezombes C.** Balasubramanian, C. Chiu, P. Doshi. Anti-tumor activity of daratumumab, a novel human CD38 monoclonal antibody, in in vitro and in vivo models of B-cell Non-Hodgkin Lymphoma. International Conference on Malignant Lymphoma, June 14-17, 2017. Lugano, Switzerland. Oral presentation.

Rossi C, Decaup E, Gravelle P, Tosolini M, Franchini DM, Laurent C, Bordenave J, Ligat L, Jean C, Pont F, Savina A, Klein C, Perez-Gala P, Poupot M, Fournié JJ, **Bezombes C.** PD-1 immune checkpoint blockade improves anti-CD20 based immunotherapy in follicular lymphoma. International Conference on Malignant Lymphoma, June 14-17, 2017. Lugano, Switzerland. Poster.

Rossi C, Decaup E, Tosolini M, Gravelle P, Ligat L, Franchini DM, Laurent C, Bordenave J, Pont F, Savina A, Klein C, Poupot M, Fournié JJ, **Bezombes C**. L'axe PD1-PDL1/2 contrôle la réponse des lymphocytes Tgamma delta dans le lymphome folliculaire. SFH, Paris, 2017, Oral presentation.

Rossi C, Bordenave J, Teyssedre L, Savina A, Klein C, Fournié JJ, Rouquette J, **Bezombes C**. Influence de la matrice extra-cellulaire dans le traitement du lymphome folliculaire : une voie thérapeutique prometteuse. SFH, Paris, 2016, Poster.

Rossi C, Decaup E, Rouquette J, Laurent C, Savina A, Klein C, Fournié JJ and **Bezombes C**. Influence of extracellular matrix on diffusion and efficacy of anti-CD20 antibody in follicular lymphoma. TOW, Toulouse, 2016, Poster.

Decaup E, Gravelle P, Jean C, Rossi C, Laurent C, Klein C, Savina A, Laurent G, Fournié JJ and **Bezombes C**. Multicellular Aggregates of Lymphoma Cells (MALC): An Invaluable 3D Model for Studying Follicular Lymphoma Pathology. ESH, Lisbonne, 2015, Poster.

Bezombes C. Le modèle 3D de LNH (Multicellular Agregates of Lymphoma Cells) : pour une meilleure compréhension de la pathologie et des mécanismes d'action de thérapies ciblées. Journées du Lysa, Bordeaux, 2015, Oral communication (invited).

Bezombes C, Decaup E, Rossi C, Gravelle, Laurent C, Klein C, Savina A, Fournié JJ. ADCC induced by monoclonal anti-CD20 antibodies in a 3D follicular lymphoma model : signaling and spatial localization. Annual meeting of American Society of Hematology, San Francisco, 2014, Poster.

Bezombes C, Decaup E, Gravelle P, Jean C, Laurent C, Klein C, Varoqueaux N, Savina A, Laurent G, Fournié JJ. MALC: un modèle d'étude en 3D du Lymphome folliculaire. Workshop Modèle 3D et applications en oncologie. GSO. Toulouse, 2013, Poster.

Bezombes C. BCR downstream signaling molecules as therapeutic targets in NHL. 3rd Workshop Normal and neoplastic B cells. Oléron, 2013. Oral communication (invited).

Bezombes C, Decaup E, Gravelle P, Jean C, Laurent C, Klein C, Varoqueaux N, Savina A, Laurent G, Fournié JJ. Multicellular Aggregates of Lymphoma Cells (MALC): an invaluable model for studying follicular lymphoma biology and mechanisms of action of therapeutic drugs such as anti-CD20 antibodies. Annual meeting of American Society of Hematology, New Orleans, 2013, Poster.

Lechevallier S, Osseni SA, Verelst M, Neumeyer D, Ferrand A, **Bezombes C**, Mauricot R. Nanoparticles as multimodal imaging agents for X-Ray tomography and photoluminescence. RITC, Toulouse, 2013, Poster.

Bezombes C. Etude de la réponse aux anticorps monoclonaux dans des modèles tridimensionnels de lymphome folliculaire. Projet émergent. 9 èmes journées du GSO, Limoges, 2013, Poster

Garmy-Susini B, Laurent C, Sarkozy C, Baseggio L, Ysebaert L, Laurent G, Berger F, **Bezombes C**. Mise en place d'un modèle de lymphome folliculaire chez la souris SCID-Beige. Etude de la lymphangiogenèse. 9 èmes journées du GSO, Limoges, 2013, Poster.

Decaup E, Jean C, Laurent C, Gravelle P, Fruchon S, Laurent G, Klein C, Varoqueaux N, Savina A, Fournié JJ, **Bezombes C**. Mechanisms of action of therapeutic monoclonal anti-CD20 antibodies in a 3D follicular lymphoma model. AAI, Honolulu, 2013, Poster.

Bezombes C. PAIR Lymphome RITUXOP ou Comment Optimiser l'Efficacité du Rituximab dans le traitement du Lymphome Folliculaire. Congrès SFH, Paris, 2013, Oral communication (invited).

Bezombes C. The Fluorescent Cell Barcoding technique: Principles and applications. 1st symposium of the CRCL, Lyon, 13-15 February 2013, Oral communication, satellite session BD biosciences (invited).

Bezombes C. Signalisation dans les lymphomes folliculaires : vers l'identification de nouvelles cibles thérapeutiques. Journée Hémopathies malignes, Toulouse, 2011, Oral communication (invited).

Bezombes C. Amélioration de l'efficacité du Rituximab dans le lymphome folliculaire. 7èmes journées du GSO, Bordeaux, 2011. Oral communication (invited).

Decaup E, Fournie JJ, Varoqueaux N, **Bezombes C.** Effets des anticorps monoclonaux thérapeutiques de 2ème et 3ème génération sur un modèle de lymphome folliculaire cultivé en 3D. 7èmes journées du GSO, Bordeaux, 2011. Poster.

Decaup E, Fournie JJ, Varoqueaux N, **Bezombes C.** Effets des anticorps monoclonaux thérapeutiques de 2ème et 3ème génération sur un modèle de lymphome folliculaire cultivé en 3D. 1ères journées du CRCT, Argelès/Mer, 2011. Poster.

Gravelle P, Jean C, **Bezombes C.**, Laurent G, and Fournié JJ. Three dimensional organization facilitates quiescence entry of Follicular Lymphoma cells. 1ères journées du CRCT, Argelès/Mer, 2011. Poster.

Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Laurent G, **Bezombes C.** Le Rituximab inhibe la signalisation du BCR. Congrès annuel de la SFH, Paris, 2010. Poster.

Kheirallah S, Ysebaert L, Leseux L, Benhadji K, Laurent G, **Bezombes C.** Enzastaurin displays activity against follicular lymphoma cells:role of mTOR pathway. 50th Annual meeting of American Society of Hematology, San Francisco, 2008. Poster.

Bezombes C., Leseux L, Rigo M, Laurent G. Identification of new targets of Rituximab in follicular lymphoma. Cancer Immunotherapy conference. Paris, 1st July 2008. Oral communication (invited).

Bezombes C., Leseux L, Rigo M, Laurent G. Caractérisation de nouveaux mécanismes d'action du Rituximab dans les lymphomes folliculaires. Conférences du groupe GDR 2352, immunociblage des tumeurs. Montpellier, 24 June 2008. Oral communication (invited).

Kheirallah S, Caron P, Gross E, Laurent G, **Bezombes C.** Etude des mécanismes d'action du Rituximab dans les lymphomes folliculaires : effet sur la signalisation du BCR. Colloque lymphocyte B, île d'Oléron, 29-31 May 2008. Poster.

Bezombes C. Role of Syk on the survival of follicular lymphoma cells. GSO axe 1/RTRS Symposium: "Cellular signaling and therapeutic targets", Toulouse, 1-2 April 2008. Oral communication.

Kheirallah S, Caron P, Gross E, Laurent G, **Bezombes C.** Etude des mécanismes d'action du Rituximab dans les lymphomes folliculaires : effet sur la signalisation du BCR. Journées de l'IFR30-31, Toulouse, November 2007. Poster.

Laurent G, Leseux L, Laurent C, Rigo M, Blanc A, **Bezombes C.** PKC zeta-mTOR pathway: a new target for Rituximab therapy in follicular lymphoma. 49TH Annual meeting of American Society of Hematology, Atlanta, 8-11 December 2007. Oral communication.

Leseux L, Hamdi SM, Al Saati T, Capilla F, Laurent G, **Bezombes C.** Régulation de la voie mTOR dans les lymphomes folliculaires. Congrès annuel de la société française d'hématologie, Paris, March 2007. Poster.

Jazirehi AR, **Bezombes C**, Laurent G, Libra M, Bonavida B. Characteristics of rituximab-resistant B-NHL clones: deficiencies in rituximab-mediated changes in lipid raft microdomains and cell signaling. Proc AACR, 2006; 47:4657. Poster.

Leseux L, Hamdi SM, Al Saati T, Capilla F, Laurent G, **Bezombes C**. Syk dependent mTOR activation in follicular lymphoma cells. 1st Meeting Dundee Toulouse, Toulouse, March 2006. Poster.

Charruyer A, **Bezombes C**, Grazide S, Jaffrézou JP and Laurent G. Roles of lipid mediators in cellular stress response after UV-C irradiation. Glycolipid & Sphingolipid Biology Gordon Conference. 8-13 January 2006, Ventura, CA. Poster

Bezombes C, Grazide S, Charruyer A, Quillet-Mary A, Jaffrézou JP, and Laurent G. Rituximab Antiproliferative Effect in B Lymphoma Cells is Associated with Acid-Sphingomyelinase Activation in Raft Microdomains. 3rd International Charleston Ceramide Conference, 2-6 March 2005, Charleston SC. Poster.

Charruyer A, Grazide S, **Bezombes C**, Laurent G, Jaffrézou JP. GERLI 1st Congres on Lipidomic, 2-5 September 2003, Paris, France. Oral communication.

Grazide S, **Bezombes C**, Fabre C, Quillet-Mary A, Jaffrézou JP, Laurent G. Rituximab anti-proliferative effect in B lymphoma cells is initiated in raft microdomains by acid sphingomyelinase activation. Second International Charleston Ceramide Conference. Como, Italia, 4-7 June 2003. Oral communication.

Grazide S, Jaffrézou JP, Maestre N, Veldman RJ, **Bezombes C**, Maddens S, Levade T, Laurent G. Ara-C and daunorubicin induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts. 44th Annual meeting of American Society of Hematology. Philadelphia, PA, 6-10 November 2002. Oral communication.

Grazide S, Maestre N, **Bezombes C**, Levade T, Laurent G, Jaffrézou JP. Implication des microdomaines membranaires dans l'apoptose induite par les agents anti-leucémiques. Congrès Club Hématopoïèse et Oncogénèse. Giens, France, 7-10 October 2001. Poster.

Bezombes C, Plo I, Mansat-De Mas V, Quillet-Mary A., Laurent G, Jaffrézou JP. Oxidative stress-induced activation of lyn recruits sphingomyelinase and is requisite for its stimulation by ara-C. 46^o Congresso Nazionale SIB. Siena, Italia, 26-29 September 2001. Poster.

Levade T, Ségui B, **Bezombes C**, Uro-Coste E, Medin JA, Andrieu-Abadie N, Chatelut M, Salvayre R, Jaffrézou JP. Lysosomal ceramide is not involved in stress-induced apoptosis. 26th Meeting of the Federation of European Biochemical Societies. Nice, France, 19-24 April 1999. Poster.

Bezombes C, Maestre N, Laurent G, Levade T, Bettaïeb A, Jaffrézou JP. Restoration of TNF- α induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. 26th Meeting of the Federation of European Biochemical Societies. Nice, France, 19-24 April 1999. Poster.

Jaffrézou JP, **Bezombes C**, Maestre N, Bettaïeb A, Levade T, Laurent G. Restoration of TNF α -induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833: evidence for neutral sphingomyelinase translocation. AACR special conference in cancer research: Molecular mechanisms of apoptosis regulation. Palm Springs, CA, 9-13 January 1998. Oral communication.

Chapter book

Bezombes C, Sibaud V. Les anticorps monoclonaux. Dermatologie et infections sexuellement transmissibles, 6^{ème} édition, Elsevier Masson, 2017.

L'Faqihi F, **Bezombes C**, Decaup E. Fluorescent Cell Barcoding : Principes et applications. La cytométrie en flux 2^{ème} édition. Parution prévue en 2018 aux éditions Lavoisier.

Laurent G, **Bezombes C**. Le concept de vectorisation antitumorale : anticorps nus et armés. Hématologie. 2009, 15: 1-9.

Bezombes C and Laurent G. Implication of sphingolipids in Rituximab-induced signaling pathway. Rituximab-mediated Molecular Signaling and Interaction with Chemotherapeutic Drugs, 2007: ISBN: 81-7895-256-4 Editor: Benjamin Bonavida.

Patent

Methods and compositions for increasing the efficiency of therapeutic antibodies using gd cell activator compounds. par **Bezombes C**, Fournié JJ, Gertner-Dardenne J, Laurent G. (2006) Brevet europeen INSERM n°EP 06291146-8, déposé le 13/07/2006, à l' Office Européen des Brevets.

Reviewing

Guest editor

Cancers 2021

Journals

Blood Cancer review

Cancers

Journal of Immunology

Molecular oncology

Oncoimmunology